Profile data is unavailable for this security.
About the company
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
- Revenue in HKD (TTM)4.71bn
- Net income in HKD3.65bn
- Incorporated2000
- Employees1.78k
- LocationHUTCHMED (China) Ltd48Th Floor, Cheung Kong Center2 Queen's Road Central Hong KongHKG
- Phone+852 21281188
- Fax+852 21281778
- Websitehttps://www.hutch-med.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Guangzhou Innogen Pharmaceutl Grp Co Ltd | -100.00bn | -100.00bn | 12.79bn | 105.00 | -- | 15.05 | -- | -- | -- | -- | -- | 1.84 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 3.39 | -- | 0.0769 | -- | -- | -- | 76.18 | -- | -- | -- |
| Everest Medicines Ltd | 963.07m | -745.25m | 13.88bn | 722.00 | -- | 2.90 | -- | 14.41 | -2.31 | -2.31 | 2.98 | 13.55 | 0.1684 | 13.97 | 3.04 | 1,448,222.00 | -13.03 | -29.28 | -14.21 | -31.67 | 69.92 | -- | -77.38 | -1,040.86 | 5.43 | -- | 0.1577 | -- | 461.16 | -- | -23.32 | -- | 16.96 | -- |
| Sihuan Pharmaceutical Holdings Group Ltd | 2.37bn | -91.22m | 15.00bn | 2.77k | -- | 3.04 | -- | 6.32 | -0.0098 | -0.0098 | 0.2572 | 0.5396 | 0.1894 | 1.49 | 3.86 | 889,784.80 | -3.05 | -3.60 | -5.01 | -5.05 | 66.29 | 73.13 | -16.08 | -19.74 | 1.61 | -1.36 | 0.1606 | -- | 2.18 | -7.96 | -301.10 | -- | -20.58 | 3.60 |
| CF PharmTech Inc | 683.23m | 31.40m | 15.03bn | 574.00 | 478.90 | 13.86 | 146.46 | 21.99 | 0.0762 | 0.0762 | 1.66 | 2.63 | -- | -- | -- | -- | -- | -- | -- | -- | 80.18 | -- | 4.60 | -- | 1.89 | -- | 0.076 | -- | 9.23 | -- | -33.53 | -- | -- | -- |
| Consun Pharmaceutical Group Ltd | 3.70bn | 1.14bn | 16.29bn | 3.07k | 14.56 | 3.35 | 13.38 | 4.41 | 1.33 | 1.33 | 4.31 | 5.77 | 0.5642 | 2.35 | 12.33 | 1,168,238.00 | 17.60 | 14.71 | 24.67 | 22.82 | 76.62 | 75.04 | 31.20 | 29.56 | 3.32 | -- | 0.0517 | 40.93 | 14.56 | 11.42 | 16.05 | 62.72 | -9.54 | 25.83 |
| Zai Lab Ltd | 3.45bn | -1.62bn | 17.10bn | 1.87k | -- | 2.82 | -- | 4.96 | -1.52 | -1.52 | 3.21 | 5.37 | 0.4119 | 3.19 | 6.53 | -- | -19.29 | -33.80 | -27.61 | -39.12 | 61.52 | 64.07 | -46.83 | -186.77 | 2.68 | -- | 0.2108 | -- | 49.59 | 98.38 | 23.17 | -- | 32.19 | -- |
| Ascletis Pharma Inc | 2.67m | -292.52m | 17.61bn | 208.00 | -- | 7.57 | -- | 6,586.39 | -0.299 | -0.299 | 0.0027 | 2.19 | 0.0011 | 0.2668 | 11.59 | 11,577.58 | -12.10 | -8.46 | -12.73 | -8.80 | 36.21 | 7.91 | -10,937.78 | -522.12 | 14.53 | -- | 0.0023 | -- | -97.73 | -62.52 | -107.95 | -- | -40.26 | -- |
| Vigonvita Life Sciences Co Ltd | -100.00bn | -100.00bn | 20.11bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -94.07 | -- | -1,848.73 | -- | -- | -- |
| HUTCHMED (China) Ltd | 4.71bn | 3.65bn | 20.31bn | 1.78k | 5.57 | 2.11 | 5.42 | 4.32 | 4.18 | 4.18 | 5.39 | 11.01 | 0.3966 | 7.09 | 3.86 | 2,598,691.00 | 30.79 | -9.55 | 40.72 | -13.77 | 44.15 | 39.84 | 77.64 | -20.32 | 4.51 | -- | 0.07 | -- | -24.80 | 25.20 | -62.56 | -- | 15.93 | -- |
| Ab&B Bio Tech Co Ltd JS | 366.27m | -253.90m | 22.39bn | 583.00 | -- | 587.93 | -- | 61.12 | -0.6453 | -0.6453 | 0.9309 | 0.0968 | -- | -- | -- | -- | -- | -- | -- | -- | 67.29 | -- | -69.32 | -- | 0.3162 | -9.49 | 0.9646 | -- | 397.65 | -- | 39.09 | -- | -- | -- |
| Shanghai Henlius Biotech Inc | 6.56bn | 932.54m | 24.40bn | 3.54k | 41.09 | 9.94 | 17.29 | 3.72 | 1.72 | 1.72 | 12.07 | 7.09 | 0.5386 | 1.73 | 5.86 | 1,866,062.00 | 7.66 | -3.21 | 13.85 | -5.76 | 75.77 | 72.50 | 14.22 | -7.87 | 0.5046 | 10.47 | 0.5185 | -- | 6.11 | 128.98 | 50.26 | -- | 10.83 | -- |
| The United Laboratories Intl. Hldgs Ltd. | 15.95bn | 3.46bn | 24.84bn | 17.40k | 6.60 | 1.30 | 5.96 | 1.56 | 1.91 | 1.91 | 8.78 | 9.69 | 0.5397 | 2.89 | 5.97 | 938,443.90 | 11.71 | 9.37 | 17.46 | 14.54 | 47.24 | 44.33 | 21.70 | 15.06 | 1.60 | -- | 0.2472 | 26.01 | 0.1387 | 10.39 | -1.54 | 32.89 | 37.25 | 45.96 |
| Sunshine Lake Pharma Co Ltd | 3.82bn | -447.94m | 25.20bn | 6.53k | -- | 56.99 | 21,090.14 | 6.60 | -0.7768 | -0.7768 | 6.62 | 0.7674 | -- | -- | -- | 582,865.20 | -- | -- | -- | -- | 73.62 | -- | -12.86 | -- | 0.7739 | -0.7591 | 0.5111 | -- | -37.06 | -- | -212.17 | -- | -- | -- |
| PegBio Co Ltd | -100.00bn | -100.00bn | 26.05bn | 58.00 | -- | 89.02 | -- | -- | -- | -- | -- | 0.7481 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 3.07 | -- | 0.2439 | -- | -- | -- | -1.49 | -- | -- | -- |
| Grand Pharmaceutical Group Ltd | 11.70bn | 2.08bn | 26.80bn | 12.44k | 12.70 | 1.54 | 10.34 | 2.29 | 0.5943 | 0.5943 | 3.35 | 4.90 | 0.4557 | 3.66 | 3.88 | 976,472.80 | 7.99 | 10.40 | 10.81 | 14.24 | 57.64 | 61.04 | 17.53 | 22.80 | 0.9872 | -- | 0.2107 | 29.12 | 10.59 | 12.06 | 31.30 | 16.49 | 0.7398 | 22.05 |
Data as of Feb 16 2026. Currency figures normalised to HUTCHMED (China) Ltd's reporting currency: Hong Kong Dollar HKD
12.31%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Aegon-Industrial Fund Management Co., Ltd.as of 30 Jun 2025 | 19.85m | 2.28% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 18.15m | 2.08% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 10.62m | 1.22% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2025 | 9.30m | 1.07% |
| FIL Investment Management (Hong Kong) Ltd.as of 31 Dec 2025 | 8.91m | 1.02% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 8.80m | 1.01% |
| Bank of China Investment Management Co., Ltd.as of 30 Jun 2025 | 8.49m | 0.97% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 8.48m | 0.97% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2025 | 7.73m | 0.89% |
| M&G Investment Management Ltd.as of 31 Oct 2025 | 7.01m | 0.80% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
